Determining optimal therapy of early-stage disease remains complicated

摘要

Large-scale randomized trials in early-stage prostate cancer are rare. Data from the recent ProtecT trial enables a cautious endorsement of active monitoring for early-stage, screen-detected prostate cancer: cancer-specific survival was high regardless of treatment approach (monitoring, surgery or radiation). How these findings apply to contemporary prostate cancer care requires careful evaluation.